Outlook Therapeutics is a pre-commercial biopharmaceutical company dedicated to developing therapies for the preservation of vision. The company works on the development of an FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, specifically for conditions like wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).

Outlook Therapeutics, Inc.

Outlook Therapeutics

Outlook Therapeutics, Inc. | 9,877 followers on LinkedIn. ONS-5010: A uniquely positioned anti-VEGF therapy for wet AMD, DME and BRVO | Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S.

Yezan Haddadin

Head of IT at Outlook Therapeutics, Inc.

Christoph Puetz

Senior Director, Drug Product Operations at Outlook Therapeutics, Inc.

Edwin Chan

Tony Moses

Our commitment to advancing retinal therapies is fueled by our passionate team. Discover their stories: https://bit.ly/4ccRdTD #OTLK #ophthalmology #retinadisease #wetAMD

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference. https://bit.ly/3UF53Id #wetAMD #ophthalmology #retinadisease

Thousands of people with a serious eye disease could be set to benefit after NICE today recommended a new treatment option. Find out more about bevacizumab gamma for treating wet age-related macular degeneration: https://lnkd.in/eJ3TsQHU #NICENews

NICE - National Institute for Health and Care Excellence

Did you know that #WetAMD is an advanced form of age-related macular degeneration? It occurs when abnormal blood vessels grow under the retina, leaking fluid and blood. This can cause swelling and damage to the macula, potentially leading to vision loss. #OTLK #Ophthalmology #RetinaDisease

Interested in our clinical progress? Learn more here: https://bit.ly/3XsbOiy #OTLK #ophthalmology #retinadisease #wetAMD

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment. https://bit.ly/4f7cHTB #wetAMD #ophthalmology #retinadisease

We are led by a proven team with extensive experience in the development and commercialization of ophthalmic therapeutics. Explore our backgrounds here: https://bit.ly/47dT9IJ . #OTLK #ophthalmology #retinadisease #wetAMD

Outlook Therapeutics is dedicated to developing therapies for the preservation of vision. #OTLK #ophthalmology #retinadisease #wetAMD

Stay in the loop! Be the first to know about our latest updates and announcements. Join us today! https://bit.ly/48ZjFXP #OTLK #Ophthalmology #RetinaDisease #WetAMD

#TuneInToday for our presentation at the Virtual Investor Closing Bell Event at 4 PM ET. Register here: https://bit.ly/4e2hsOj #OTLK #Ophthalmology #RetinaDisease #WetAMD

OUTL

COM:OUTLOOKTHERAPEUTICS

Outlook Therapeutics

locale

market

industry

website

linkedin

investor of

Metrics